Serif Biomedicines is pioneering Modified DNA as a new class of biotechnology. Founded in 2021 within Flagship Labs, the innovation foundry of Flagship Pioneering, Serif integrates nucleic acid chemistry, synthetic biology, delivery science, and artificial intelligence to enable programmable, scalable, durable, and redosable DNA medicines. The company's initial focus is on genetically defined diseases and reprogramming the immune system.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/27/26	$50,000,000		Flagship Pioneering	undisclosed